Letter from the Editor

Contributed by:

Taren Grom, Editor

NOTE: The content below contains the first few paragraphs of the printed article and the titles of the sidebars and boxes, if applicable.

America’s pharmaceutical industry is helping the process of healing the nation in the wake of September 11th. Within hours of the terrorist attacks on New York and Washington, America’s pharmaceutical companies responded with medicines and vaccines, supplies for workers and rescuers, and aid for victims and their families. According to PhRMA, for the first time in history, the country’s emergency pharmaceutical stock pile, stored at eight secret sites around the nation, was mobilized and deployed. Tons of pharmaceuticals and medical supplies including 84,000 I.V. fluid packs, 400 ventilators, and 50,000 doses of tetanus vaccine to protect rescue workers were sent to both New York and Washington. To date, companies have pledged more than $80 million in contributions toward disaster relief. Following are just a few examples of how America’s pharmaceuti cal companies responded to these disas ters. One company sent 20,000 bottles of eye solution for rescue workers and donat ed an artificial skin product for burn vic tims. Another company supplied a disas ter module containing wound care and personalcare products to New York’s St. Vincent’s Hospital. Immediately after the attack another company obtained emer gency “compassionate use” approval from the FDA for a burn cream now in Phase III trials and rushed shipment to a burn center in New York. In addition to products and services, many pharmaceutical companies, too many to list individually, have committed to huge donation programs to help the relief efforts. Pfizer, which is based in New York City, announced donations totaling more than $10 million to relief efforts. The Pfizer Foundation’s donation includes $5 million for various relief funds. In addition, contributions by Pfiz er employees to relief organizations relat ed to this emergency will be matched by the company. “In the more than 150 years Pfizer has been based in New York, no greater tragedy has affected the people of our city,” says Hank McKinnell, Pfizer chair man and CEO. “The attacks in New York and Washington were attacks on us all. Now, we stand ready to do whatever we can to help those in need.” American Home Products is donating $5 million to the relief effort. Aventis made a $1 million contribution to the American Red Cross, in addition, phar maceutical products and vaccines were contributed to immediately support local medical services. Johnson & Johnson pledged a package of $10 million in financial and product aid to the relief efforts. Pharmacia, together with its Mon santo agricultural subsidiary, has commit ted to an initial donation of $1 million. GlaxoSmithKline has donated $1 million. Novartis announced a $3 million dona tion. Abbott Laboratories has committed $2 million to the relief efforts. TAP Phar maceutical Products has donated $500,000. In the weeks and months ahead, America’s pharmaceutical companies and their employees have pledged to continue to join in the great national effort to heal the wounds that America suffered during these tragic events. Taren Grom Editor Aportion of the advertising dollars from this issue has been donated to the American Red Cross Disaster Relief Fund. PUBLISHER Lisa Banket EDITOR Taren Grom CREATIVE DIRECTOR Marah Walsh CONTRIBUTING EDITORS Diane Hoffman Virginia Kirk Denise Myshko Kim Ribbink Deborah Ruriani Lynda Sears Copyright 2001 by PharmaLinx LLC, Titusville, NJ Printed in the U.S.A. Volume One, Number Three PharmaVoice is published six times per year by PharmaLinx LLC, P.O.Box 327, Titusville, NJ 08560. Postmaster: Send address changes to PharmaVoice, P.O. Box 327, Titusville, NJ 08560. PharmaVoice Coverage and Distribution: Domestic subscriptions are available at $84 for one year (6 issues). Foreign subscriptions: 6 issues US$165. Contact PharmaVoice at P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your order to 609.730.0197. Contributions: PharmaVoice is not responsible for unsolicited contributions of any type. Unless other wise agreed in writing, PharmaVoice retains all rights on material published in PharmaVoice for a period of six months after publication and reprint rights after that period expires. Change of address: Please allow six to eight weeks for a change of address. Send your new address along with your subscription label to PharmaVoice, P.O. Box 327, Titusville, NJ 08560. Call us at 609.730.0196 or FAX your change to 609.730.0197. IMPORTANT NOTICE: The post office will not forward copies of this magazine. PharmaVoice is not respon sible for replacing undelivered copies due to lack of or late notification of address change. Advertising in PharmaVoice: To advertise in Pharma Voice please contact our Advertising Department at P.O.Box 327, Titusville, NJ 08560, or telephone us at 609.730.0196. Email: lbanket@pharmalinx.com. www.pharmalinx.com THE FORUM FOR THE INDUSTRY EXECUTIVE Volume 1 . Number 3 Send your letters to feedback@pharma linx.com. Please include your name, title, company, and business phone number. Let ters chosen for publication may be edited for length and clarity. All submissions become the property of PharmaLinx LLC. Letters A 4 N o v e mb e r / D e c e m b e r 2 00 1 PharmaVOICE

Posted in:

Post a Comment

You must be logged in to post a Comment.

FEEDBACK